SCHEMBL4471532

SCHEMBL4471532

Cc1ccc(Cl)c(-c2ccc(CN3CCN(C(=O)c4ccccc4)C(c4ccccc4)C3)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.59
P2RX7 Q99572 1/20 0.48
TACR1 P25103 6/20 0.42
TACR2 P21452 4/20 0.42
EIF4A3 P38919 3/20 0.42
S1PR1 P21453 1/20 0.42
S1PR5 Q9H228 1/20 0.42
CYP46A1 Q9Y6A2 1/20 0.41
HSP90AA1 P07900 1/20 0.41
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA4 P22748 2/20 0.40
CA9 Q16790 2/20 0.40
MGLL Q99685 2/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4481910 0.90 CNR2 (0.61) CNR2P2RX7TACR1TACR2S1PR1
SCHEMBL4472734 0.89 CNR2 (0.59) CNR2P2RX7TACR1TACR2S1PR1
SCHEMBL4467170 0.88 CNR2 (0.54) CNR2P2RX7TACR1TACR2EIF4A3
SCHEMBL4476258 0.88 CNR2 (0.58) CNR2P2RX7TACR1TACR2S1PR1
SCHEMBL4477636 0.88 CNR2 (0.58) CNR2P2RX7TACR1TACR2PTGDR2
SCHEMBL4477211 0.88 CNR2 (0.58) CNR2P2RX7TACR1TACR2S1PR1
SCHEMBL4471995 0.86 CNR2 (0.56) CNR2P2RX7S1PR1S1PR5
SCHEMBL4465014 0.86 CA1 (0.56) CNR2CYP46A1CA1CA2CA4
SCHEMBL4472224 0.83 CNR2 (0.66) CNR2P2RX7S1PR1S1PR5
SCHEMBL4477428 0.81 CNR2 (0.64) CNR2P2RX7S1PR1S1PR5CYP46A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 CNR2 2/4885P2RX7 196/4885TACR1 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.